[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sickle-cell-anemia-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sickle-cell-anemia-in-children":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100634521","development-of-a-provider-focused-intervention-to-improve-health-outcomes-in-pediatric-sickle-cell-disease-100634521",false,"NCT07540767","Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease","Inclusion Criteria:\n\n* Licensed health care provider (HCP) who provides care to youth with SCD\n* HCP employed by Connecticut Children's, Yale New Haven Children's Hospital, or Children's Hospital of Philadelphia and primary work area is Hematology\u002FOncology\n\nExclusion Criteria:\n\n* HCP who does not provide care to youth with SCD\n* HCP is a medical trainee, not including fellows\n* HCP not employed by CT Children's, Yale New Haven Children's Hospital, or Children's Hospital of Philadelphia\n* Not fluent in English",true,"ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this interventional study is to learn about the impact of an intervention for health care providers that teaches individuation and perspective-taking (IPT) skills to enhance patient-centered communication in pediatric sickle cell disease (SCD). The main question it aims to answer is:\n\nDoes an intervention that teaches individuation and perspective-taking (IPT) skills to pediatric sickle cell disease (SCD) health care providers (HCPs) enhance patient-centered communication?\n\nResearchers will compare the IPT intervention to a control group who will receive education about SCD pain management to see if the IPT intervention improves patient-centered communication.\n\nParticipants will complete baseline surveys and then be randomly assigned into the intervention or control group. After completing their assigned session (IPT training or education), they will be asked to complete the same surveys as completed at baseline.",[26,27,28,29,30],"Sickle Cell Disease","Sickle Cell Anemia in Children","Sickle Cell Disease (SCD)","Sickle Cell","Sickle Cell Anemia (HbSS)",[32,33],"sickle cell","pediatrics","NOT_YET_RECRUITING","2026-04-24",{"date":37,"type":38},"2026-04-29","ACTUAL",{"date":40,"type":20},"2027-09-01",{"date":42,"type":20},"2030-06-30",{"name":44,"class":45},"Connecticut Children's Medical Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100573194","hypoxic-red-blood-cells-in-sickle-cell-anemia-100573194","NCT06743113","Hypoxic Red Blood Cells in Sickle Cell Anemia","A Multi-Center, Randomized, Controlled, Cross-Over Study to Evaluate the Effectiveness of Hypoxic Red Blood Cells Processed With the Hemanext ONE® System Versus Conventional Red Blood Cells in Patients With Transfusion Dependent Sickle Cell Anemia","Inclusion Criteria:\n\n1. Male or female at least 7 years of age;\n2. Are able to provide informed consent, and assent as applicable, to participate in the study;\n3. Diagnosis of Sickle Cell Anemia (SCA) (HbSS, HbSβ0 thalassemia) with participation in a chronic transfusion program and have undergone regular transfusions during at least 6 months prior to Screening;\n4. Have had an average interval of at least 14 days between RBC transfusions over the past 6 months;\n5. If on iron chelation therapy, have been on a stable dose for ≥3 months prior to screening;\n\nExclusion Criteria:\n\n1. Are not exclusively transfused at the site;\n2. Have a diagnosis of HbSC disease, HbSβ+ thalassemia or another SCD variant (excluding HbSS and HbSβ0 thalassemia)\n3. Are routinely transfused with washed, packed RBC units;\n4. Have received hemoglobin inducers (e.g. erythropoietin) in the 30 days prior to Screening;\n5. Are currently being evaluated for gene therapy;\n6. Have any clinically significant pulmonary, cardiovascular, endocrine, hepatic, gastrointestinal, renal, infectious, immunological (including significant allo- or auto-immunization) disease, considered not adequately controlled prior to the study;\n7. Are a female of child-bearing potential who is pregnant or planning to become pregnant in the next 14 months;\n8. Have a history of allo-immunization that cannot be managed by the local blood bank;\n9. Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol;\n10. Is a ward of the state, prisoner, or transient","7 Years",{"count":56,"type":20},48,[23],"The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.",[60,61,27,62],"Sickle Cell Anaemia","Sickle Cell Anemia Crisis","Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)","2026-01-06",{"date":65,"type":38},"2026-01-07",{"date":67,"type":20},"2026-03",{"date":69,"type":20},"2028-09",{"name":71,"class":72},"Hemanext","INDUSTRY",6,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":46},"100461229","phase-3-promoting-utilization-and-safety-of-hydroxyurea-using-precision-in-africa-100461229","NCT05285917","Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa","BrUOG 419 - Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSHUP)","PUSHUP","Inclusion Criteria:\n\n* Diagnosis of sickle cell anemia (HbSS or HbS\u002FB0-thalassemia)\n* Age 6 months- 12 years of age at enrollment\n* Parent or guardian willing and able to provide written or informed consent\n* Weight ≥ 7.5 kg (temporary exclusion)\n\nExclusion Criteria:\n\n* Splenomegaly with evidence of hypersplenism as defined by platelet count \\\u003C150,000, hemoglobin \\\u003C5 g\u002FdL or absolute neutrophil count \\\u003C1.0 x10\\^9\u002FL\n* Hydroxyurea use within the past 6 months\n* Blood transfusion within the past 6 months (temporary exclusion)\n* Pregnancy\n* Pre-existing severe hematologic toxicity, as defined by platelet count \\\u003C80,000, hemoglobin \\\u003C4 regardless of ANC; hemoglobin \\\u003C6 AND ARC \\\u003C100; hemoglobin \\\u003C7 AND ARC \\\u003C80 x10\\^9\u002FL (temporary exclusion)","6 Months","12 Years",{"count":85,"type":20},400,[87],"PHASE3","Sickle cell anemia (SCA) is among the world's most common and devastating blood disorders, affecting more than 300,000 newborns per year. Most infants with SCA are born in the low-resource settings of sub- Saharan Africa, where an estimated 50-90% will die before 5 years of age due to lack of early diagnosis and appropriate care. Hydroxyurea is a safe and effective once-daily oral medication that has become the standard of care for the treatment of children with SCA in high-resource settings. There is now a growing body of evidence to support the safety and clinical benefits of hydroxyurea for the treatment of SCA in sub-Saharan Africa. The requirement for frequent laboratory monitoring, uncertainties about appropriate, most effective dosing, and the concern for hematologic laboratory toxicities, however, will continue to limit widespread hydroxyurea utilization and real-world effectiveness. The investigators have recently developed and prospectively evaluated an individualized, pharmacokinetics-guided hydroxyurea dosing strategy for children with SCA that has demonstrated optimal clinical and laboratory benefits with minimal toxicity. In this research study, the investigators aim to extend this precision medicine approach to Africa.",[27,26],"RECRUITING","2025-04-07",{"date":93,"type":38},"2025-04-09",{"date":95,"type":38},"2023-11-15",{"date":40,"type":20},{"name":98,"class":45},"Brown University"]